Can contemporary transrectal prostate biopsy accurately select candidates for hemi-ablative focal therapy of prostate cancer?
- PMID: 19191784
- DOI: 10.1111/j.1464-410X.2009.08347.x
Can contemporary transrectal prostate biopsy accurately select candidates for hemi-ablative focal therapy of prostate cancer?
Abstract
Objective: To determine if biopsy characteristics can be used to identify men with unilateral prostate cancer on radical prostatectomy (RP) pathological specimens, thereby selecting candidates for hemi-ablative focal therapy.
Patients and methods: Of 1458 men who had RP from January 2000 to June 2007, we identified 590 of 880 evaluable patients with unilateral disease on their preoperative biopsy. Charts were reviewed to record preoperative prostate-specific antigen (PSA) level, high-grade prostatic intraepithelial neoplasia (HGPIN), clinical stage, Gleason score, perineural invasion (PNI), prostate volume, number of positive cores, and percentage of positive cores. Final surgical pathology was evaluated for unilateral cancer. Univariate analysis was used (logistic regression method) to identify independent predictors of unilateral disease on the RP specimen. A subset analysis was done in men with low-risk disease, defined as clinical stage T1C, Gleason score <7 and a PSA level of <10 ng/mL.
Results: Of 590 men with unilateral disease on biopsy, 163 (27.3%) had unilateral disease on the RP specimen. Pathological features, including HGPIN (P = 0.714), Gleason score (P > 0.608), PNI (P = 0.714), number of positive cores (P = 0.076), percentage of cores positive (P = 0.056), prostate volume (P = 0.285), and PSA level (P = 0.062) did not improve the prediction of unilateral disease. When men with unilateral cancer were further stratified to include only those with low-risk disease, 28.4% had unilateral disease on the RP specimen. None of the biopsy or clinical features evaluated were predictors of unilateral disease on the RP specimen.
Conclusion: Unilateral prostate cancer on biopsy predicts unilateral disease on RP pathology in only 27.6% of cases. The predictive ability is not improved by adding biopsy and clinical characteristics. Additional methods are needed to accurately identify men appropriate for focal therapy.
Similar articles
-
Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy.BJU Int. 2012 Jul;110(2 Pt 2):E64-8. doi: 10.1111/j.1464-410X.2011.10762.x. Epub 2011 Nov 17. BJU Int. 2012. PMID: 22093108
-
The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.Cancer. 2003 Dec 1;98(11):2344-50. doi: 10.1002/cncr.11809. Cancer. 2003. PMID: 14635068
-
Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan.BJU Int. 2006 Sep;98(3):549-53. doi: 10.1111/j.1464-410X.2006.06379.x. BJU Int. 2006. PMID: 16925752
-
Prostate biopsy: who, how and when. An update.Can J Urol. 2005 Feb;12 Suppl 1:44-8; discussion 99-100. Can J Urol. 2005. PMID: 15780165 Review.
-
The role of perineural invasion and other biopsy characteristics as prognostic markers for localized prostate cancer.Semin Urol Oncol. 1998 Aug;16(3):124-8. Semin Urol Oncol. 1998. PMID: 9741416 Review.
Cited by
-
Parameters predicting postoperative unilateral disease in patients with unilateral prostate cancer in diagnostic biopsy: a rationale for selecting hemiablative focal therapy candidates.Can Urol Assoc J. 2013 Jan-Feb;7(1-2):E82-7. doi: 10.5489/cuaj.268. Can Urol Assoc J. 2013. PMID: 23671513 Free PMC article.
-
Final Results of a Phase I/II Multicenter Trial of WST11 Vascular Targeted Photodynamic Therapy for Hemi-Ablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Performed in the United States.J Urol. 2016 Oct;196(4):1096-104. doi: 10.1016/j.juro.2016.05.113. Epub 2016 Jun 9. J Urol. 2016. PMID: 27291652 Free PMC article. Clinical Trial.
-
Do contemporary imaging and biopsy techniques reliably identify unilateral prostate cancer? Implications for hemiablation patient selection.Cancer. 2019 Sep 1;125(17):2955-2964. doi: 10.1002/cncr.32170. Epub 2019 May 1. Cancer. 2019. PMID: 31042322 Free PMC article.
-
PSA density lower cutoff value as a tool to exclude pathologic upstaging in initially diagnosed unilateral prostate cancer: impact on hemiablative focal therapy.World J Urol. 2012 Feb;30(1):91-5. doi: 10.1007/s00345-010-0631-6. Epub 2010 Dec 31. World J Urol. 2012. PMID: 21193912
-
Volumetric modulated arc therapy planning for primary prostate cancer with selective intraprostatic boost determined by 18F-choline PET/CT.Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):1017-25. doi: 10.1016/j.ijrobp.2014.12.052. Int J Radiat Oncol Biol Phys. 2015. PMID: 25832692 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous